Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Characterization of the metabolic and inflammatory role of GIPR signalling in astrocytes

EF 2023-24

Résumé
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) regulate glucose metabolism and body weight through the activation of GIPR and GLP-1R, respectively, which are expressed in different organs, including the brain. Recent preclinical and clinical studies show that GIPR and GLP-1R agonists attenuate the pathophysiological processes that underlie Alzheimer’s and Parkinson’s disease, showing promising therapeutic effects. The molecular mechanisms driving these neuroprotective effects are unclear, but of high importance for the targeted use of GIPR and GLP-1R agonists in the treatment and of neurogenerative diseases. This project aims to delineate the mechanistic pathways engaged by GIPR signaling that modulate metabolism and neuroinflammation, focusing specifically on the role of GIPR in the astrocytes. Astrocytes can adopt a pro-inflammatory state in response to pathological conditions, contributing to the progression of neurodegenerative diseases. Thus, an astrocyte-specific GIPR knockout (GiprAST-/-) mouse will be characterized and fed a regular or high-fat diet while treated with GIPR agonist or vehicle. The metabolic phenotype of GiprAST-/- and control groups will be assessed using gold-standard methods such as glucose tolerance tests. In addition, astrocytes isolated from GiprAST-/- and control mice will be cultured and evaluated for their susceptibility to pro-inflammatory stimuli when treated with GIPR agonist or vehicle. RNA-sequencing and unbiased discovery proteomics will be used to measure changes in inflammatory markers and signaling pathways regulated by astrocyte GIPR signalling. This novel GiprAST-/- mouse model will provide clinically relevant insight into the role of astrocyte GIPR in metabolism and central inflammation.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506020
Name
Fang Susanna
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of the metabolic and inflammatory role of GIPR signalling in astrocytes
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Astrocytes; Brain; Central Nervous System; Diabetes; Energy Homeostasis; Glucose Metabolism; Glucose-Dependent Insulinotropic Polypeptide; Incretin; Neurodegenerative Disease; Neuroinflammation
Abstract
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) regulate glucose metabolism and body weight through the activation of GIPR and GLP-1R, respectively, which are expressed in different organs, including the brain. Recent preclinical and clinical studies show that GIPR and GLP-1R agonists attenuate the pathophysiological processes that underlie Alzheimer’s and Parkinson’s disease, showing promising therapeutic effects. The molecular mechanisms driving these neuroprotective effects are unclear, but of high importance for the targeted use of GIPR and GLP-1R agonists in the treatment and of neurogenerative diseases. This project aims to delineate the mechanistic pathways engaged by GIPR signaling that modulate metabolism and neuroinflammation, focusing specifically on the role of GIPR in the astrocytes. Astrocytes can adopt a pro-inflammatory state in response to pathological conditions, contributing to the progression of neurodegenerative diseases. Thus, an astrocyte-specific GIPR knockout (GiprAST-/-) mouse will be characterized and fed a regular or high-fat diet while treated with GIPR agonist or vehicle. The metabolic phenotype of GiprAST-/- and control groups will be assessed using gold-standard methods such as glucose tolerance tests. In addition, astrocytes isolated from GiprAST-/- and control mice will be cultured and evaluated for their susceptibility to pro-inflammatory stimuli when treated with GIPR agonist or vehicle. RNA-sequencing and unbiased discovery proteomics will be used to measure changes in inflammatory markers and signaling pathways regulated by astrocyte GIPR signalling. This novel GiprAST-/- mouse model will provide clinically relevant insight into the role of astrocyte GIPR in metabolism and central inflammation.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fang, Susanna
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~